Dr Eric Mayes is CEO of Endomag and has over 20 years’ experience in developing and leading materials technology companies spanning data storage, display technology, printed electronics and medical devices. Eric has led oncology-focused Endomag through its rapid growth since marketing its first device for staging breast cancer in late 2012, which has now been used in over 40,000 procedures across 35 countries. Prior to joining Endomag in 2010, Eric served as Director of Commercial Development for Cambridge Display Technology (CDT) that was sold to Sumitomo Chemical in 2007 for $285m. Prior to CDT, he served as CEO of NanoMagnetics that developed high performance materials for the data storage industry. For that founding role, he was named the Royal Society of Chemistry’s “Entrepreneur of the Year 2003”. With a strong interest in supporting the translation of scientific research, Eric lectures internationally on nanomaterials commercialisation and technology entrepreneurship. He is an advisor to the University of Texas at Austin’s “Texas Health Catalyst” and the European Healthtech Translation Advisory Board (HealthtechTAB). A US-UK dual national, he holds a BSc in Physics from Arkansas State University and a PhD in Chemistry from the University of Bath. Eric is a Fellow of the Royal Society of Chemistry.